Patents by Inventor IKUMI Shiga

IKUMI Shiga has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
    Patent number: 10144933
    Abstract: Problem The purpose of the present invention is to provide: a chiral nucleic acid adjuvant having immunity-inducing activity and an immunity-inducing activator. Solution The present invention relates to an adjuvant which comprises oligonucleotides which comprise two to four sequences each represented by 5?-X1CpG X2-3? and has a length of 14 to 32 nucleotides, wherein a nucleic acid at 3? end side of at least two CpG motifs is connected by phosphorothioate linkage, wherein each nucleic acids at 3? end and 5? end of the oligonucleotide is S type nucleic acids connected by phosphorothioate linkage, and wherein the oligonucleotide comprises at least one nucleic acid without phosphorothioate modification. The present invention relates to an immunity-inducible activator comprising the adjuvant.
    Type: Grant
    Filed: January 14, 2015
    Date of Patent: December 4, 2018
    Assignees: SHIN NIPPON BIOMEDICAL LABORATORIES, LTD., WAVE LIFE SCIENCES JAPAN, INC.
    Inventors: Takefumi Gemba, Ryoichi Nagata, Ikumi Shiga
  • CHIRAL NUCLEIC ACID ADJUVANT HAVING IMMUNITY INDUCTION ACTIVITY, AND IMMUNITY INDUCTION ACTIVATOR
    Publication number: 20160333349
    Abstract: Problem The purpose of the present invention is to provide: a chiral nucleic acid adjuvant having immunity-inducing activity and an immunity-inducing activator. Solution The present invention relates to an adjuvant which comprises oligonucleotides which comprise two to four sequences each represented by 5?-X1CpG X2-3? and has a length of 14 to 32 nucleotides, wherein a nucleic acid at 3? end side of at least two CpG motifs is connected by phosphorothioate linkage, wherein each nucleic acids at 3? end and 5? end of the oligonucleotide is S type nucleic acids connected by phosphorothioate linkage, and wherein the oligonucleotide comprises at least one nucleic acid without phosphorothioate modification. The present invention relates to an immunity-inducible activator comprising the adjuvant.
    Type: Application
    Filed: January 14, 2015
    Publication date: November 17, 2016
    Inventors: Takefumi GEMBA, Ryoichi NAGATA, IKUMI Shiga